[HTML] frontiersin.org

[HTML][HTML] Repurposing of the antiepileptic drug levetiracetam to restrain neuroendocrine prostate cancer and inhibit mast cell support to adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni, V Cancila… - Frontiers in …, 2021 - frontiersin.org
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …
被引用次数：11 相关文章
[PDF] scienceopen.com

[PDF][PDF] Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni… - Front. Immunol. 12 …, 2021 - scienceopen.com
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …
[HTML] frontiersin.org

[HTML][HTML] Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni, V Cancila… - Frontiers in …, 2021 - frontiersin.org
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni, V Cancila… - FRONTIERS IN …, 2021 - air.uniud.it
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni, V Cancila… - 2021 - ricerca.unityfvg.it
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …

[引用][C] Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni… - … in Immunology (Web), 2021 - jglobal.jst.go.jp
Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate
Cancer and Inhibit Mast Cell Support to Adenocarcinoma | Article Information | J-GLOBAL …

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.

R Sulsenti, B Frossi, L Bongiovanni… - Frontiers in …, 2021 - europepmc.org
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …
[PDF] unipa.it

[PDF][PDF] Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni, V Cancila… - Front. Immunol. 12 …, 2021 - iris.unipa.it
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …
[HTML] nih.gov

[HTML][HTML] Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

R Sulsenti, B Frossi, L Bongiovanni… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …